[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380788-105":59,"doc-detail-380788-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","response-to-capmatinib-in-a-met-fusion-positive-cholangiocarcinoma","Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma","","Cholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma, and metastatic or unresectable cases typically receive gemcitabine-based doublet therapy first. Further lines lack standardized options, while MET fusions are rare and the benefit of MET inhibitors is insufficiently characterized. This report describes a chemotherapy-refractory metastatic cholangiocarcinoma patient harboring a CAPZA-2-MET fusion and MET amplification who showed a dramatic response to capmatinib, a targeted MET tyrosine kinase inhibitor.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/response-to-capmatinib-in-a-met-fusion-positive-cholangiocarcinoma/380788/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/response-to-capmatinib-in-a-met-fusion-positive-cholangiocarcinoma/380788.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment was used first for metastatic or unresectable cholangiocarcinoma in this document?","Question",{"text":112,"@type":113},"The recommended first-line treatment described is a gemcitabine-based doublet, most commonly gemcitabine plus cisplatin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular finding made capmatinib use clinically relevant in this case?",{"text":117,"@type":113},"The tumor harbored a CAPZA-2-MET fusion along with MET amplification, predicted to form a chimeric protein with an intact MET kinase domain.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the patient respond to capmatinib?",{"text":121,"@type":113},"The patient demonstrated a dramatic response to capmatinib after chemotherapy-refractory disease.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380788,1790809741,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma  \nAnthony Turpin1, Clotilde Descarpentries2, Valérie Grégoire3, Olivier Farchi2, Alexis B. Cortot4, Philippe Jamme5,*,  \n1Medical Oncology Department, CHU Lille, University of Lille, Lille, France  \n2Department of Biochemistry and Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, University of Lille, Lille, France 3 Pathology Department, CHU Lille, University of Lille, Lille, France  \n4Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France  \n5Department of Dermatology, Hopital Claude Huriez, CHU Lille, University of Lille, France  \n*Corresponding author: Philippe Jamme, PhD, Department of Dermatology, Hopital Claude Huriez, CHU of Lille, rue Michel Polonowski, 59000, France. E-mail: [philippe.jamme@chru-lille.fr](philippe.jamme@chru-lille.fr)  \nAbstract  \nCholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended first-line treatment is gemcitabine-based doublet, most commonly gemcitabine and cisplatin. There is no standard treatment for further lines. MET fusions are rare alterations described in many cancers. The efficacy of specific MET inhibitors is poorly studied. We present the case of a patient with chemotherapy-refractory metastatic cholangiocarcinoma harboring a CAPZA-2-MET fusion along with MET amplification who dramatically responded to capmatinib, a specific MET tyrosine kinase inhibitor.  \nKey words: MET; cholangiocarcinoma; resistance, precision medicine.  \nGenomic terms and nomenclature: ALK: anaplastic lymphoma kinase; BRAF: B-rapidly accelerated fibrosarcoma; CAPZA2: F-actin-capping protein subunit alpha-2; FGFR: fibroblast growth factor (receptor); FISH: fluorescence in situ hybridization; FOLFOX: leucovorin calcium (folinic acid), fluorouracil, andoxaliplatin; HLA-DRB1: HLA class II histocompatibility antigen; DRB1: beta chain; IDH1: isocitrate dehydrogenase 1; IHC: immunochemistry; KIF5B: kinesin-1 heavy chain; NSCLC: non-small cell lung cancer; OCA: oncomine comprehensive assay; PARP: poly(ADP-ribose) polymérase; PTPRZ1: receptor-type tyrosineprotein phosphatase zeta 1; TKI: tyrosine kinase inhibitor.  \nKey Points  \n• This case report is believed to be the first demonstrating clinical efficacy of MET TKI in a cholangiocarcinoma patient with a CAPZA-2-MET fusion.  \n• The patient has shown a significant response allowing access to a localized treatment.  \nIntroduction  \nIntrahepatic cholangiocarcinoma (iCCA) is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended firstline treatment is a gemcitabine-based doublet, most commonly gemcitabine and cisplatin. FOLFOX regimen is the current standard of care in second-line setting, based on the ABC-06 trial with improved survival compared with active symptom management.1 The prognosis remains poor with a median survival of less than 12 months.2 Several targeted therapies are currently being evaluated including FGFR, IDH1, PARP, and BRAF inhibitors.3 MET inhibitors have also been tested in cholangiocarcinoma. Cabozantinib, anon-specific MET tyrosine kinase inhibitor (TKI), was evaluated as a single agent in a phase II trial in patients with  \nchemotherapy-refractory cholangiocarcinoma, but showed poor efficacy (median PFS 1.7 months, median OS 5.2 months) .4 In this study, one patient with 3 + MET expression in the tumor stayed on treatment for 278 days; however, MET expression did not correlate with outcome in the overall study population. Tivantinib, another non-specific MET TKI, was evaluated in a phase I trial in combination with gemcitabine in patients with solid tumor. Eight patients with cholangiocarcinoma were included and one partial response was observed.5 Circulating c-MET was measured in blood samples at baseline and after treatment and was not correlated with tumor response.5 ","cbCaiauxl1kqXd95","https://ap.wps.com/l/cbCaiauxl1kqXd95","pdf",5533124,"English","# Abstract\n## Key words\n## Genomic terms and nomenclature\n## Key Points\n## Introduction\n## Patient Story\n## Molecular Tumor Board","[{\"question\":\"What treatment was used first for metastatic or unresectable cholangiocarcinoma in this document?\",\"answer\":\"The recommended first-line treatment described is a gemcitabine-based doublet, most commonly gemcitabine plus cisplatin.\"},{\"question\":\"What molecular finding made capmatinib use clinically relevant in this case?\",\"answer\":\"The tumor harbored a CAPZA-2-MET fusion along with MET amplification, predicted to form a chimeric protein with an intact MET kinase domain.\"},{\"question\":\"How did the patient respond to capmatinib?\",\"answer\":\"The patient demonstrated a dramatic response to capmatinib after chemotherapy-refractory disease.\"}]","Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma | PDF",1790242138]